Proton pump inhibitors (PPIs) and histamine H2-receptor antagonists (H2RAs) are essential therapeutic agents globally, and are primarily used for managing acid-related gastrointestinal disorders such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger–Ellison syndrome [1]. This evidence concerns the gene HRH2 and gastroesophageal reflux disease.